Plain language review: the safety of relugolix combination therapy for advanced prostate cancer.
Saved in:
| Title: | Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. |
|---|---|
| Authors: | La Cerda J; Urology San Antonio, San Antonio, TX, USA., Thorley J; Intermountain Healthcare, Murray, UT, USA., Sieber P; Urological Associates of Lancaster, Lancaster, PA, USA., Cookson MS; Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Flanders SC; Sumitomo Pharma America Inc., Cambridge, MA, USA., Gatoulis SC; Pfizer Inc., New York, NY, USA., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2025 Jan; Vol. 21 (1), pp. 51-62. Date of Electronic Publication: 2024 Nov 06. |
| Publication Type: | Patient Education Handout |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-8301 |
|---|---|
| DOI: | 10.1080/14796694.2024.2409543 |
